Scar - Pipeline Review, H2 2016
Summary
Global Markets Direct’s, ‘Scar - Pipeline Review, H2 2016’, provides an overview of the Scar pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Scar, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Scar and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Scar
- The report reviews pipeline therapeutics for Scar by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Scar therapeutics and enlists all their major and minor projects
- The report assesses Scar therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Scar
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Scar
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Scar pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Scar Overview 9
Therapeutics Development 10
Pipeline Products for Scar - Overview 10
Pipeline Products for Scar - Comparative Analysis 11
Scar - Therapeutics under Development by Companies 12
Scar - Therapeutics under Investigation by Universities/Institutes 14
Scar - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Scar - Products under Development by Companies 18
Scar - Products under Investigation by Universities/Institutes 19
Scar - Companies Involved in Therapeutics Development 20
3M Drug Delivery Systems 20
Albireo AB 21
Altacor Limited 22
Beech Tree Labs, Inc. 23
Clanotech AB 24
Escape Therapeutics, Inc. 25
FirstString Research, Inc. 26
LegoChem Biosciences, Inc 27
Moerae Matrix, Inc. 28
Promore Pharma 29
RXi Pharmaceuticals Corporation 30
VBS Pharmaceuticals 31
Scar - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
A-3914 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
A-5425 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
BTL-slo - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
CLT-28643 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
decorin - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Drug to Agonize Beta 2 Receptor for Wound Scars - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
FibroStem - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
FS-2 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Granexin - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
ICX-RHY - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
LCB-030110 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
MG-53 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
MMI-0100 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Monoclonal Antibody to Inhibit LRG1 for AMD, Diabetic Retinopathy, Oncology and Scar - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
nefopam hydrochloride - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
OLX-101 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Polysaccharide for Wounds and Scars - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
PXL-01 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Recombinant Protein for Immunology, Dermatology, Oncology and Musculoskeletal Disorders - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
Recombinant Protein for Scar - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
RXI-109 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
S-34240 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
tranilast - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
Scar - Dormant Projects 76
Scar - Discontinued Products 77
Scar - Product Development Milestones 78
Featured News & Press Releases 78
Aug 18, 2016: ScarX announces approval for trial of first clinically-promising scar reduction cream 78
Apr 28, 2016: RXi Pharmaceuticals Announces Advancement of its Ophthalmology Franchise with Successful Topical Delivery of sd-rxRNA to the Cornea in an in vivo Corneal Wound Model 79
Apr 25, 2016: RXi Pharmaceuticals to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference 80
Apr 19, 2016: RXi Pharmaceuticals Fortifies its Novel RNAi Patent Portfolio with Notice of Allowance for Lead Clinical Candidate RXI-109 80
Mar 31, 2016: Rxi Pharmaceuticals Strengthens Intellectual Property Portfolio for Dermal Indications 81
Mar 28, 2016: RXi Pharmaceuticals to Present at the Oligonucleotide Therapeutics and Delivery Conference 82
Feb 16, 2016: Accel-Rx/BDC make second portfolio investment in ScarX Therapeutics 82
Oct 12, 2015: RXi Pharmaceuticals to Present at Premier Scientific Plastic Surgery Meeting 83
Oct 05, 2015: RXi Pharmaceuticals Bolsters Protection for its Novel Self-Delivering RNAi Platform with Notice of Allowance from USPTO 84
Sep 29, 2015: RXi Pharmaceuticals to Present at Dawson James Securities Growth Stock Conference 84
Sep 28, 2015: RXi Pharmaceuticals Granted Patent in China for Lead Clinical Candidate RXI-109 85
Jun 02, 2015: RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 85
Mar 23, 2015: RXi Pharmaceuticals Reports Positive Advancements in its Dermatology Programs at the Occasion of the 73rd Annual Meeting of the American Academy of Dermatology 85
Dec 17, 2014: RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 87
Sep 29, 2014: RXi Pharmaceuticals to Present at the 13th Annual BIO Investor Forum 88
Appendix 89
Methodology 89
Coverage 89
Secondary Research 89
Primary Research 89
Expert Panel Validation 89
Contact Us 89
Disclaimer 90
List Of Tables
List of Tables
Number of Products under Development for Scar, H2 2016 10
Number of Products under Development for Scar - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Development, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Investigation by Universities/Institutes, H2 2016 19
Scar - Pipeline by 3M Drug Delivery Systems, H2 2016 20
Scar - Pipeline by Albireo AB, H2 2016 21
Scar - Pipeline by Altacor Limited, H2 2016 22
Scar - Pipeline by Beech Tree Labs, Inc., H2 2016 23
Scar - Pipeline by Clanotech AB, H2 2016 24
Scar - Pipeline by Escape Therapeutics, Inc., H2 2016 25
Scar - Pipeline by FirstString Research, Inc., H2 2016 26
Scar - Pipeline by LegoChem Biosciences, Inc, H2 2016 27
Scar - Pipeline by Moerae Matrix, Inc., H2 2016 28
Scar - Pipeline by Promore Pharma, H2 2016 29
Scar - Pipeline by RXi Pharmaceuticals Corporation, H2 2016 30
Scar - Pipeline by VBS Pharmaceuticals, H2 2016 31
Assessment by Monotherapy Products, H2 2016 32
Number of Products by Stage and Target, H2 2016 34
Number of Products by Stage and Mechanism of Action, H2 2016 36
Number of Products by Stage and Route of Administration, H2 2016 38
Number of Products by Stage and Molecule Type, H2 2016 40
Scar - Dormant Projects, H2 2016 76
Scar - Discontinued Products, H2 2016 77
Lisst Of Figures
List of Figures
Number of Products under Development for Scar, H2 2016 10
Number of Products under Development for Scar - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Products, H2 2016 17
Assessment by Monotherapy Products, H2 2016 32
Number of Products by Top 10 Targets, H2 2016 33
Number of Products by Stage and Top 10 Targets, H2 2016 33
Number of Products by Top 10 Mechanism of Actions, H2 2016 35
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 35
Number of Products by Routes of Administration, H2 2016 37
Number of Products by Stage and Routes of Administration, H2 2016 37
Number of Products by Molecule Types, H2 2016 39
Number of Products by Stage and Top 10 Molecule Types, H2 2016 39
